Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Previous treatment analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

doi:10.1016/j.jaad.2018.05.607

Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Previous treatment analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.607 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB147

Keyword(s):

Randomized Controlled Trials ◽

Previous Treatment ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.07.002 ◽

2019 ◽

Vol 80 (1) ◽

pp. 128-138.e2 ◽

Cited By ~ 20

Author(s):

Dee Anna Glaser ◽

Adelaide A. Hebert ◽

Alexander Nast ◽

William P. Werschler ◽

Lawrence Green ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis: Pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.1178 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB298

Keyword(s):

Randomized Controlled Trials ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

DRM04 for the treatment of primary axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.419 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB105

Keyword(s):

Randomized Controlled Trials ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Glycopyrronium cloth improves axillary hyperhidrosis across a broad spectrum of patients: Post hoc analyses of the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials in patient subpopulations

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.797 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB217

Keyword(s):

Randomized Controlled Trials ◽

Broad Spectrum ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Phase 3 ◽

Randomized Controlled ◽

Spectrum Of Patients ◽

Post Hoc

Download Full-text

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0395-0 ◽

2018 ◽

Vol 20 (1) ◽

pp. 135-145 ◽

Cited By ~ 9

Author(s):

David M. Pariser ◽

Adelaide A. Hebert ◽

Janice Drew ◽

John Quiring ◽

Ramanan Gopalan ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Patient Reported Outcomes ◽

Phase Iii ◽

Controlled Trials ◽

Axillary Hyperhidrosis ◽

Randomized Controlled ◽

Patient Reported

Download Full-text

Rationale and design of two, phase 3, randomized controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory and unexplained chronic cough

World Allergy Organization Journal ◽

10.1016/j.waojou.2020.100203 ◽

2020 ◽

Vol 13 (8) ◽

pp. 100203

Author(s):

David Muccino ◽

George Philip ◽

A.H. Morice ◽

S.S. Birring ◽

L. Mcgarvey ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Receptor Antagonist ◽

Chronic Cough ◽

Controlled Trials ◽

P2x3 Receptor ◽

Phase 3 ◽

Two Phase ◽

Randomized Controlled

Download Full-text

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

Diabetes Therapy ◽

10.1007/s13300-020-00803-3 ◽

2020 ◽

Vol 11 (6) ◽

pp. 1347-1367 ◽

Cited By ~ 3

Author(s):

Shrita Patel ◽

Anne Hickman ◽

Robert Frederich ◽

Susan Johnson ◽

Susan Huyck ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Randomized Controlled Trials ◽

Pooled Analysis ◽

Controlled Trials ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Safety and tolerability of cancer drugs studied in phase 3 randomized controlled trials (RCTs) over the last decade.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6588 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6588-6588

Author(s):

Domen Ribnikar ◽

Hadar Goldvaser ◽

Alberto Ocana ◽

Arnoud J. Templeton ◽

Bostjan Seruga ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Controlled Trials ◽

Cancer Drugs ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Risk of hematological and gastrointestinal toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e16184 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e16184-e16184

Author(s):

Anita Sultan ◽

Kyaw Zin Thein ◽

Sriman Swarup ◽

Somedeb Ball ◽

Lukman Aderoju Tijani ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Neuroendocrine Tumors ◽

Meta Analysis ◽

Controlled Trials ◽

Phase 3 ◽

Randomized Controlled

Download Full-text

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.03.040 ◽

2018 ◽

Vol 79 (2) ◽

pp. 287-293 ◽

Cited By ~ 15

Author(s):

Linda Stein Gold ◽

Mark G. Lebwohl ◽

Jeffrey L. Sugarman ◽

David M. Pariser ◽

Tina Lin ◽

...

Keyword(s):

Randomized Controlled Trials ◽

Plaque Psoriasis ◽

Fixed Combination ◽

Controlled Trials ◽

Phase 3 ◽

Safety And Efficacy ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Download Full-text